ASP388B / Astellas - LARVOL DELTA

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=392 | Recruiting | Sponsor: Astellas Pharma Global Development, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Monotherapy • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • ALK • BRAF • CD276 • EGFR • HER-2 • PD-1 • PD-L1

A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors (clinicaltrials.gov) - P1/2 | N=392 | Not yet recruiting | Sponsor: Astellas Pharma Global Development, Inc.

Monotherapy • New P1/2 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • ALK • BRAF • CD276 • EGFR • HER-2 • PD-1 • PD-L1